Aura Biosciences, Inc. AURA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.19M-25.3% | $1.54M-24.1% | $1.82M-19.6% | $1.68M-31.5% | $1.59M-40.6% | ||
| $27.96M+19.8% | $21.9M-2.0% | $22.18M+30.2% | $22.88M+35.6% | $23.34M+36.9% | ||
| $6.91M+21.3% | $5.34M-2.4% | $5.73M-7.6% | $5.73M-2.6% | $5.69M+8.2% | ||
| $34.87M+20.1% | $27.24M-2.0% | $27.91M+20.1% | $28.61M+25.7% | $29.04M+30.1% | ||
| -$34.87M-20.1% | -$27.24M+2.0% | -$27.91M-20.1% | -$28.61M-25.7% | -$29.04M-30.1% | ||
| $1.19M-24.1% | $1.69M-15.2% | $1.8M-19.3% | $1.64M-32.3% | $1.57M-40.8% | ||
| -$33.67M-22.6% | -$25.54M+1.0% | -$26.1M-24.3% | -$26.97M-32.6% | -$27.47M-39.7% | ||
| $11K-38.9% | $15K-37.5% | $26K-39.5% | $48K— | $18K-60.9% | ||
| -$33.69M-22.6% | -$25.56M+1.1% | -$26.13M-24.2% | -$27.02M-32.9% | -$27.48M-39.5% | ||
| -$0.50+9.1% | -$0.37+28.8% | -$0.40+4.8% | -$0.47-14.6% | -$0.55-37.5% | ||
| -$0.50+9.1% | -$0.37+28.8% | -$0.40+4.8% | -$0.47-14.6% | -$0.55-37.5% | ||
| 67.4M+34.6% | 60.3M+21.5% | 65.9M+32.8% | 58M+17.1% | 50.1M+1.4% | ||
| 67.4M+34.6% | 60.3M+21.5% | 65.9M+32.8% | 58M+17.1% | 50.1M+1.4% | ||
| -$33.79M-22.2% | -$25.73M+1.7% | -$26.09M-28.8% | -$27.1M-31.9% | -$27.64M-36.7% | ||
| $1.19M-25.3% | $1.54M-24.1% | $1.82M-19.6% | $1.68M-31.5% | $1.59M-40.6% | ||
| -$78K+43.1% | -$11K+96.8% | $57K-92.8% | -$88K+56.2% | -$137K+73.7% | ||
| -$27K-28.6% | -$160K-12,700% | -$13K-940% | $8K+740% | -$21K-1,580% | ||
| $2K+108% | $149K+503% | -$13K+48.0% | -$36K-38.5% | -$24K+25.0% | ||
| -$34.87M-20.1% | -$27.24M+2.0% | -$27.91M-20.1% | -$28.61M-25.7% | -$29.04M-30.1% | ||
| -$34.59M-20.3% | -$26.97M+2.0% | -$27.61M-20.4% | -$28.31M-26.0% | -$28.74M-30.6% | ||
| -$34.59M-20.3% | -$26.97M+2.0% | -$27.61M-20.4% | -$28.31M-26.0% | -$28.74M-30.6% | ||
| -$34.87M-20.1% | -$27.24M+2.0% | -$27.91M-20.1% | -$28.61M-25.7% | -$29.04M-30.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aura Biosciences, Inc. profitable?
- Aura Biosciences, Inc. is not currently profitable: it reported a net loss of $112.4M over the trailing twelve months.
- What is Aura Biosciences, Inc.'s earnings per share?
- Aura Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-1.74.
- Where does Aura Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Aura Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.